Gossamer Bio (GOSS) Cash & Equivalents (2018 - 2026)
Gossamer Bio (GOSS) reported Cash & Equivalents of $41.15 million for Q2 2026, up 56.4% from $26.31 million a year earlier and up 0.3% from the prior quarter.
Powered by 
Analysis
Gossamer Bio (GOSS) Cash & Equivalents (2018 - 2026) Analysis & Trends
At the end of FY2025, Gossamer Bio posted Cash & Equivalents of $37.73 million, down 18.1% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -40.0% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $46.07 million in FY2024 (+43.5%), $32.11 million in FY2023 (-71.3%), $111.97 million in FY2022 (-38.9%) and $183.4 million in FY2021 (-62.3%).
- The Q2 2026 figure ranks as the highest quarterly Cash & Equivalents since Q4 2024.
- Year over year, Cash & Equivalents gained in three of the last eight quarters, with an average decline of 13.3%.
- The high point for year-over-year Cash & Equivalents in five years was Q2 2024 (growth of 134.8%); the low point was Q2 2022 (a decline of 72.5%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $41.03 million (Q1 2026), $37.73 million (Q4 2025) and $8.93 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,144.36 Bn | 1,112.95 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.36 Bn | 555.22 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 502.79 Bn | 475.90 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.08 Bn | 310.46 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 300.87 Bn | 264.86 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 264.31 Bn | 237.99 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 239.07 Bn | 194.47 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.50 Bn | 168.70 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.00 Bn | 117.64 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Gossamer Bio | 37.12 Mn | -436.28 Mn | - | 41.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.15 Mn |
| Mar 31, 2026 | 41.03 Mn |
| Dec 31, 2025 | 37.73 Mn |
| Sep 30, 2025 | 8.93 Mn |
| Jun 30, 2025 | 26.31 Mn |
| Mar 31, 2025 | 29.02 Mn |
| Dec 31, 2024 | 46.07 Mn |
| Sep 30, 2024 | 28.46 Mn |
| Jun 30, 2024 | 86.88 Mn |
| Mar 31, 2024 | 38.86 Mn |
| Dec 31, 2023 | 32.11 Mn |
| Sep 30, 2023 | 82.61 Mn |
| Jun 30, 2023 | 37.00 Mn |
| Mar 31, 2023 | 65.24 Mn |
| Dec 31, 2022 | 111.97 Mn |
| Sep 30, 2022 | 153.48 Mn |
| Jun 30, 2022 | 94.32 Mn |
| Mar 31, 2022 | 138.91 Mn |
| Dec 31, 2021 | 183.40 Mn |
| Sep 30, 2021 | 213.47 Mn |
API Access
Gossamer Bio Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GOSS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "GOSS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GOSS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();